Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2,2'-Dithiodiethanesulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL18847 | 0.94 | KDM4E (0.48) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL835426 | 0.94 | KDM4E (0.41) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL835029 | 0.94 | KDM4E (0.48) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL837033 | 0.94 | KDM4E (0.41) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL835186 | 0.94 | KDM4E (0.41) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL835873 | 0.91 | KDM4E (0.46) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL8403162 | 0.91 | KDM4E (0.46) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL834581 | 0.82 | KDM4E (0.39) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| SCHEMBL8459850 | 0.82 | BBOX1 (0.39) | KDM4EMAPTALOX15GMNNALDH1A1 | |
| 2,2'-Dithiodiethanesulfonic Acid SCHEMBL7050821 | 0.82 | KDM4E (0.39) | KDM4EMAPTALOX15GMNNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5902610-A | ADMINISTERING WITH OR WITHOUT CISPLATIN IN THE SAME FORMULATION, TO REDUCE TOXIC SIDE EFFECTS OF CISPLATIN IN CANCER THERAPY AND POTENTIATE ITS ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-05-11 | — | — | US | claimed |
| US-20230220481-A1 | Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane Sulfonate | LANTERN PHARMA INC. | 2023-07-13 | — | — | US | disclosed |
| CN-115397405-A | Method for determining sensitivity to 2,2' -dithiobisethane sulfonate | 蓝腾制药公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-4087609-A1 | METHOD FOR DETERMINING SENSITIVITY TO 2,2'-DITHIO-BIS-ETHANE SULFONATE | Lantern Pharma Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021142460-A1 | METHOD FOR DETERMINING SENSITIVITY TO 2,2'-DITHIO-BIS-ETHANE SULFONATE | LANTERN PHARMA INC. (US) | 2021-07-15 | — | — | WO | disclosed |
| EP-1991237-B1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2252246-B1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS INC (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8143236-B2 | For reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, chemotherapy-associated toxicities; nucleosides | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8026227-B2 | For reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, chemotherapy-associated toxicities; nucleosides | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| EP-2252246-A1 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7282602-B2 | Medicinal disulfide salts | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2007-10-16 | — | — | US | disclosed |
| WO-2007070599-A2 | CHEMOPROTECTIVE METHODS AND COMPOSITIONS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1797031-A1 | MEDICINAL DISULFIDE SALTS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070135519-A1 | Chemoprotective methods and compositions | BIONUMERIK PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006034327-A1 | MEDICINAL DISULFIDE SALTS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063949-A1 | Medicinal disulfide salts | LANTERN PHARMA INC. | 2006-03-23 | — | — | US | disclosed |
| US-5902610-A | ADMINISTERING WITH OR WITHOUT CISPLATIN IN THE SAME FORMULATION, TO REDUCE TOXIC SIDE EFFECTS OF CISPLATIN IN CANCER THERAPY AND POTENTIATE ITS ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| US-5866617-A | AQUEOUS SOLUTION FOR ADMINISTRATION TO PATIENTS ALSO RECEIVING CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5866169-A | LYOPHILIZED FORMULATION WITH CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5866615-A | LYOPHILIZED FORMULATION WITH ANTICANCER AGENTS; REDUCED SIDE EFFECTS, INCREASED ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063949-A1 | Medicinal disulfide salts | MPST, TST, STS | KDM4E 4330/4885MAPT 2637/4885ALOX15 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.